FDA Extends Comment Period for NDI Draft Guidance
Interested parties will now have until December 12, 2016 to submit comments on FDA’s revised new dietary ingredient (NDI) draft guidance-a 60-day extension over the previous deadline.
Photo by iStockphoto.com/ImageGap
FDA announced this morning it will be extending the public comment period for its revised new dietary ingredient (NDI) draft guidance. The extension announcement, which will be formally published in the Federal Register tomorrow, sets the new deadline for public comments as December 12, 2016-a 60-day extension over the previous deadline.
It’s been nearly two months since FDA released its revised NDI guidance, with industry reaction ranging from resistant to receptive. Several industry associations also requested an extension to the original deadline for public comment (October 17), including the American Herbal Products Association (Silver Spring, MD), the Natural Products Association (Washington, DC), the Council for Responsible Nutrition (Washington, DC), and the United Natural Products Alliance (Salt Lake City).
In its announcement, FDA says it is extending the comment period “in response to requests to extend the comment period to allow interested persons additional time to submit comments.”
Instructions for submitting comments can be found here.
Read more:
Is GRAS Still a Viable NDI Workaround?
How FDA’s NDI Guidance Could Paralyze Industry
Which Ingredient Categories Would Be Hit Hardest by FDA’s NDI Draft Guidance?
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
